Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fabrazyme Extension Study in Fabry Disease
NCT00074971Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 1999
- Modality
- Replacement Enzymes
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Primary endpoints: Safety and efficacy and Morphologic assessment of GL-3 inclusions in the capillary endothelium (vasculature) of the kidney. Started Oct 1999; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00074971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074971.